Research Article
Development of an HPLC-UV Method for the Analysis of Drugs Used for Combined Hypertension Therapy in Pharmaceutical Preparations and Human Plasma
Table 1
Patients and administered drugs.
| Patient number | Age | Gender | Druga and dose | Drugb substance | Time period after last administration | Coadministered drug | Coadministered drug substance and dose |
| 1 | 79 | F | Co-Diovan 160 mg/12,5 mg | VAL, HCT | 8 | Aricept | 5 mg dorepezil HCl | 2 | 52 | F | Norvasc 10 mg | AML | 12 | Mentopin Micardis | 200 mg acetylcysteine 80 mg telmisartan | 3 | 80 | F | Norvasc 10 mg | AML | 6 | Glukofen | 850 mg metformin HCl | 4 | 63 | M | Exforge 5/160 mg | AML, VAL | 8 | Ator | 10 mg atorvastatin | 5 | 71 | F | Diovan 160 mg | VAL | 8 | Apranax | 275 mg naproxen sodium | 6 | 65 | M | Hipersar Plus 20 mg/12.5 mg | OLM, HCT | 7 | Lipitor | 20 mg atorvastatin | 7 | 74 | M | Sevikar HCT 40 mg/10 mg/25 mg | OLM, AML, HCT | 8.5 | Pletal | 10 mg cilestazol | 8 | 56 | F | Cardopan Plus 80 mg/12.5 mg | VAL, HCT | 24 | Sirdalud | 2 mg tizanidine |
|
|
Drugs that have been used for hypertension therapy.
bThe active substances of the antihypertensive drugs.
|